5 Key Takeaways
-
1
Aflibercept 8 mg shows improved visual outcomes in treatment-naïve and treatment-experienced patients with wet AMD and DME.
-
2
Treatment-naïve patients achieved a 12-week injection interval after 6 months with aflibercept 8 mg.
-
3
Patients with wet AMD gained an average of 4 letters of vision, while those with DME gained 5 letters.
-
4
Treatment-experienced patients switching from aflibercept 2 mg to 8 mg extended their injection interval by 2 weeks.
-
5
The analysis utilized the IRIS registry database, following over 13,000 eyes for up to one year.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
